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Objective—A double-blind, randomized controlled trial showed that low-dose glucocorticoid
therapy in pediatric ARDS patients is feasible and may improve both ventilation and oxygenation
indices in these patients. However, the molecular mechanisms underlying potential changes in
outcomes remain unclear. Based on these clinical findings, this study was designed to examine the
effects of intravenous methylprednisolone on circulating inflammatory biomarkers in pediatric
ARDS patients.
Design—Double-blind, placebo-controlled randomized trial with blood collection on study entry
and day 7.
Setting—Tertiary care children’s hospital.
Patients—Children (0–18 years) with ARDS undergoing mechanical ventilation.

Author Manuscript

Interventions—35 children were randomized within 72 hours of mechanical ventilation. The
glucocorticoid group received methylprednisolone 2 mg/kg loading dose followed by 1 mg/kg/day
continuous infusion from days 1–7. Both groups were ventilated following the ARDSnet
recommendations. WBC and differential cell counts, plasma cytokines and CRP levels, and
coagulation parameters were analyzed on days 0 and 7.

Author Manuscript

Results—At study entry, the placebo group had higher IL-15 and basophil levels. On day 7, in
comparison to study entry, the placebo group had lower IL-1α, IFN-γ and IL-10 levels. The
glucocorticoid group had lower INF-α, IL-6, IL-10, MCP-1, G-CSF and GM-CSF levels, and
higher IL-17α levels on day 7 in comparison to study entry. Total and differential cell counts
remained unchanged within the placebo group between days 0 and 7, whereas in the
glucocorticoid group total WBC and platelets counts were increased on day 7. Pearson’s
correlation studies within the placebo and glucocorticoid groups revealed positive and negative
correlations between cytokine levels, cell counts, coagulation parameters and relevant clinical
parameters of disease severity identified in our previous study. Multiple regression models
identified several cytokines as predictors for alterations in clinical parameters of disease severity.
Conclusion—This pilot study shows the feasibility of simultaneously measuring multiple
inflammatory cytokines, cell counts and coagulation parameters in pediatric ARDS patients. We
report statistical models that may be useful for future, larger trials to predict ARDS severity and
outcomes.
Keywords
ARDS; lung injury; cytokines; chemokines; mediators; pediatrics; steroids; glucocorticoids;
inflammation
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INTRODUCTION
The clinical constellation of acute hypoxia and bilateral chest X-ray infiltrates was first
described by Ashbaugh in 1967[1] and was later defined as “Acute Respiratory Distress
Syndrome” (ARDS) by the American-European Consensus Conference (AECC) in 1994[2].
Although mortality rates in both the adult[3] and pediatric populations[4] are declining,
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substantial morbidity persists[5], resulting in a steadily increasing burden on our health care
budget.

Author Manuscript

Despite the clinical consequences and health care costs associated with ARDS, the
development of new therapeutic strategies has faced multiple challenges over the years.
Currently, oxygen supplementation and lung-protective ventilation strategies remain the
cornerstones of ARDS treatment, although ultimately both therapies can exacerbate preexisting lung damage and promote pro-inflammatory cytokine release[6]. Multiple other
therapies including nitric oxide[7], surfactant[8], prostaglandins[9], fluid balance[10] and
high frequency ventilation[11] have failed to improve survival rates. To ameliorate the
exaggerated pulmonary and systemic proinflammatory response occurring in ARDS
patients, intravenous glucocorticoid therapy has been studied in the adult population[12].
Early initiation of low-dose glucocorticoid therapy appears to provide particular therapeutic
benefits in adults by reducing lung injury scores, ventilator days and mortality rates[13].

Author Manuscript

The scarcity of new therapeutic approaches for ARDS is partly related to our lack of
understanding the underlying molecular mechanisms promoting this disease. Dysregulation
of inflammatory mediator secretion both locally and systemically contributes to the
development of ARDS. Plasma IL-1β, IL-6, IL-8, and IL-10 levels are elevated in adult
ARDS patients[14], while TNF-α and IL-6 levels are increased in the BAL fluid[15].
Importantly, both serum and BAL cytokine levels correlate with increased mortality
rates[15]. The large majority of these findings were obtained in adult studies and our
knowledge about changes in inflammatory markers in pediatric ARDS patients is very
limited[16]. As the pulmonary and immune systems of children are still in development,
differences in their immune and inflammatory responses compared to adults are to be
expected.
Not only are inflammatory mediator signaling networks incredibly complex but we also lack
a clear understanding of their cellular sources. While macrophages, neutrophils and
lymphocytes are known to produce a variety of pro- and anti-inflammatory mediators in the
lung[17, 18], we have recently confirmed that alveolar epithelial cells also secrete
substantial amounts of inflammatory cytokines[19–21]. Due to the complexity of cytokine
signaling and cellular interactions, which ultimately determine the inflammatory
microenvironment in the lungs of ARDS patients, employing a broad-spectrum antiinflammatory approach by using intravenous glucocorticoids constitutes a reasonable
clinical approach while we continue our search for more specific molecular targets.
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The effects of intravenous glucocorticoid therapy in the pediatric population, including
potentially adverse consequences for the developing child, are poorly defined. We recently
reported the first randomized controlled pilot trial showing the feasibility of
methylprednisolone therapy in children with ARDS and potential improvements in their
oxygenation, ventilation and plateau pressures[22]. However, the molecular mechanisms
underlying these clinical changes remained unknown. This study builds on the changes in 5
clinical parameters identified in our previous publication[22]. These included (1) P/F ratio
on day 8, (2) plateau pressures (PP) on day 2, (3) pCO2 levels on day 2, (4) racemic
epinephrine requirement following extubation, and (5) O2 requirement at PICU discharge.
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This is the first attempt to dissect the molecular mechanisms responsible for the observed
alterations in these 5 clinical parameters by determining alterations in pro- and antiinflammatory mediator concentrations in response to early, low-dose intravenous
glucocorticoid therapy. In this follow-up study our main goal consisted in identifying
potential ARDS biomarkers such as cytokines, cell counts, CRP levels and coagulation
parameters and to determine potential relationships between these changes and predictors of
disease severity.

MATERIALS AND METHODS
Study protocol

Author Manuscript
Author Manuscript

A total of 35 children (0–18 years) diagnosed with ARDS as defined by the Berlin
definition[23] were initially randomized to placebo or glucocorticoid groups within 72 hours
of mechanical ventilation as described in our previous study[22] (ClinicalTrials.gov number:
NCT01274260). Briefly, exclusion criteria for study enrollment were exposure to
glucocorticoids at the time of screening, terminal illness, hospice care, immunosuppressed
status, extensive burns, adrenal insufficiency, vasculitis, diffuse alveolar hemorrhage,
invasive fungal infection, chronic liver disease, gastrointestinal bleed within the past 1
month, or conditions with an estimated 6-month mortality of >50%. The steroid and placebo
groups were similarly matched (p>0.05) in regards to the following patient characteristics:
sex, race, PRISM III score, PIM-2 score, P/F ratio, PEEP, tidal volume, mean airway
pressure, blood gas pH. PaCO2, and number of lobes affected on chest X ray. Furthermore,
ARDS etiologies were similar between the two groups with pneumonia being the most
common cause, followed in order of frequency by bronchiolitis, aspiration, trauma, TRALI,
near drowning, hydrocarbon ingestion, preterm birth, and asthma. The duration of
mechanical ventilation was 9.74±6.62 vs 9.59±5.21 days in the glucocorticoid and the
placebo group (p=0.94), respectively. Two patients died in the placebo group, whereas all
survived in the glucocorticoid group (p=0.15). No patients abandoned the study.
Importantly, although we enrolled a total of 35 patients into our study, the number of
patients across all study days was not a constant for either group since the numbers of
patients in both groups decreased with increasing number of days. Not all cytokines were
present in all subjects and by day 7 some patients from each study group had improved and
were no longer on a ventilator. Therefore, each table contains the number of patients in
which a certain cytokine or inflammatory parameter was detected or studied.

Author Manuscript

Pediatric ARDS was defined as (1) acute onset of disease (within 7 days) that could not be
explained by acute left heart failure, (2) new, bilateral infiltrates on chest X ray consistent
with parenchymal pulmonary disease, and (3) P/F ratio <300[23]. Both study groups were
mechanically ventilated on the Servo i ventilators (Maquet, Inc.) in a patient-regulated
volume control (PRVC) mode, with or without synchronized intermittent mandatory
ventilation (SIMV), and with tidal volumes of 6–8 ml/kg (based on ideal body weight in
obese children and actual body weight in non-obese children), as suggested by the ARDSnet
recommendations modified for children[24].
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Glucocorticoid group patients received methylprednisolone 2 mg/kg loading dose followed
by 1 mg/kg/day continuous infusions from day 1 to day 7. The placebo group received
equivalent saline infusions.
Blood sample collection
On days 0 and 7 of the study, we collected 1 ml of whole blood in a lavender-top, K2EDTAcontaining tube. The samples were manually transferred on ice within 30 min from the blood
draw to the hospital laboratory and centrifuged for 10 min at 1000 × g at 4°C. Plasma
samples were stored at −80°C. Clinically required WBC and differential cell counts, Creactive protein (CRP) levels and coagulation parameters (PT, PTT, fibrinogen) from days 0
and 7 were retrospectively analyzed when available.
Luminex assay

Author Manuscript

Plasma mediator concentrations were determined using the Millipore Human Cytokine panel
(Millipore, Billerica, MA) following the manufacturer’s instructions. All samples were run
in duplicates (or triplicates if plasma was available); 38 mediators were assayed and
concentrations were expressed in [pg/mL]: EGF, eotaxin, FGF-2, Flt3L, fractalkine, G-CSF,
GM-CSF, GRO, IFN-α2, IFN-γ, IL-1α, IL-1β, IL-1RA, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7,
IL-8, IL-9, IL-10, IL-12(p40), IL-12(p70), IL-13, IL-15, IL-17α, IP-10, MCP-1, MCP-3,
MDC, MIP-1α, MIP-1β, sCD40L, TGF-α, TNF-α, TNF-β and VEGF.
Statistical analyses
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Univariate (descriptive statistics, frequency distributions), bivariate (Fisher’s test for
variability, t-tests, Pearson’s correlations) and multivariate analyses (linear regressions using
the least squares method) were used to evaluate the effects of glucocorticoids in pediatric
ARDS. StatPlus (AnalystSoft, Inc.) was used for generating descriptive statistics and
frequency distributions for all variables (cytokines, chemokines, and growth factors) at days
0 and 7 for the placebo and glucocorticoid groups. Prism 6 (GraphPad Software, Inc.) was
used for bivariate analyses comparing within and between the glucocorticoid vs. placebo
groups at days 0 and 7. Depending on the data distribution, we used either the unpaired t-test
(parametric) or the Mann-Whitney U test (nonparametric) for group comparisons. We also
generated a correlation matrix for pairwise associations of Pearson correlation coefficients
with simultaneously run t-tests. These results were used for pathway analysis of the
measured mediators.

Author Manuscript

Pairs of variables demonstrating strong correlation coefficients (R ≥0.7, p ≤0.01) were used
for building multivariate regression models to predict the 5 relevant clinical outcomes
reported in our previous study[22], which included PaO2/FiO2 (P/F) ratio on day 8, plateau
pressure and PaCO2 on day 2, racemic epinephrine following extubation, and supplemental
oxygen at PICU discharge.
Bivariate correlation matrices and bar graphs were prepared using only raw data without
adjustment or imputation of missing data points. Rarely, imputation of missing values for
immune mediators was necessary to build the multivariate regression models explaining or
contributing to glucocorticoid treatment-associated clinical outcomes. Immune mediator
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values falling at or below the standard curve were assigned the lowest value on the
generated standard curve. Immune factors falling at or above the standard curve were
assigned the highest value on the generated standard curve. Since these were exploratory
hypothesis-generating analyses we did not make corrections for multiple comparisons
between groups.
The number of subjects (n) per group is listed in each table legend. We selected a 95%
confidence interval.

RESULTS
1. Plasma cytokine levels, WBC counts, CRP levels, and coagulation tests

Author Manuscript

a. Between-group differences—No baseline differences in any of the 38 cytokines
occurred on day 0 between the placebo and GC groups, except for higher IL-15 levels in the
placebo group (Table 1A and Figure 1A). We found no differences in total WBC counts
(including neutrophils, monocytes, lymphocytes, eosinophils and basophils), platelet counts,
CRP levels and coagulation parameters (including PT, PTT and fibrinogen levels) between
the placebo and GC groups on day 0.
On day 7, the difference in IL-15 levels between the placebo and the GC groups was no
longer present. Although total WBC and platelet counts remained unchanged between the
two groups, basophil percentages were elevated on day 7 in the placebo group (Table 1B
and Figure 1A). We had insufficient data points for statistical analysis of CRP levels, PT,
PTT, and fibrinogen levels on day 7.

Author Manuscript

b. Within-group (time-dependent) changes—By day 7, compared to study entry, the
placebo group (Table 2 and Figure 1B) had lower IL-1α, IFN-γ, and IL-10 levels but no
changes occurred in total and differential WBC (neutrophils, monocytes, lymphocytes,
eosinophils and basophils) counts, platelet counts, PT, PTT, fibrinogen or CRP levels.
By day 7, compared to study entry, the GC group (Table 3, Figures 1B and 1C) had
increased IL-17α levels but lower IFN-α, IL-6, IL-10, MCP-1, G-CSF and GM-CSF levels.
The GC group also showed increased platelet and total WBC counts, without any changes in
differential WBC counts.
2. Pairwise correlations of serum cytokines and other parameters

Author Manuscript

Candidate biomarkers demonstrating differences between the placebo and GC groups, or
between days 0 and 7 within these groups, were analyzed as Pearson correlations. Tables 4
and 5 depict positive and negative relationships between cytokines, cell counts, non-cellular
inflammatory markers (PT, PTT, fibrinogen, CRP), and the 5 relevant clinical outcomes
identified in our previous study[22], specifically: (1) P/F ratio on day 8, (2) plateau
pressures (PP) on day 2, (3) PCO2 levels on day 2, (4) racemic epinephrine requirement
following extubation, and (5) O2 requirement at PICU discharge.
a. In the Placebo Group—Although only IL-15 levels were increased on day 0 in the
placebo group compared to the GC group, IL-15 positively correlated with MIP-1β levels on
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day 7 and negatively with monocyte counts on day 0 (Table 4). O2 requirement at ICU
discharge and racemic epinephrine after extubation were also positively correlated with
IL-15 levels on day 7.
Other cytokines of particular interest were IL-1α, IFN-γ and IL-10 since they were
decreased on day 7 (Table 2). IL-1α levels in the placebo group on day 0 positively
correlated with eotaxin, GM-CSF, IL-10, IL-7, MIP-1α, MIP-1β and TNF-α levels.
Interestingly, IL-1α levels positively correlated with the anti-inflammatory cytokine IL-10
but not with the WBC counts, CRP levels or coagulation parameters (PT, PTT, fibrinogen).
O2 requirement at ICU discharge also positively correlated with IL-1 α levels on day 0.

Author Manuscript

IFN-γ levels on day 0 positively correlated with Flt-3L, fractalkine, IL-17α, IL-1RA and
IP-10 levels. On day 7, IFN-γ levels positively correlated with racemic epinephrine
requirement after extubation.
IL-10 levels on day 0 positively correlated with eotaxin, Flt-3L, GM-CSF, IL-1RA, IL-1α,
IL-6, IL-7, IP-10, MCP-1, MIP-1β and TNF-α levels, as well as with PT and PTT levels. On
day 7, IL-10 levels in the placebo group positively correlated with Flt-3L, IL-6, IL-8,
MCP-1 and MIP-1α levels. Interestingly, IL-10 levels on both days 0 and 7 positively
correlated with O2 requirement at ICU discharge in the placebo group.
b. In the GC Group—Cytokines of particular interest were IL-17α, IFN-α, IL-10, IL-6,
MCP-1, G-CSF and GM-CSF since their levels were altered on day 7 compared to day 0
(Table 3).

Author Manuscript

IL-17α positively correlated with IL-2 levels on day 0 (Table 5), but not with any other
cytokines, cell counts, CRP levels, coagulation parameters, or clinical outcomes.
On day 0, IFN-α levels positively correlated with IL-1RA, IL-7, IL-8, MCP-1 levels and
monocyte counts (Table 5). This positive correlation between IFN-α levels and monocyte
counts persisted on day 7.
IL-10 levels positively correlated on day 0 with EGF, fractalkine, IFN-α, GRO, IL1RA,
IL-8, MCP-1, and MIP-1α, whereas on day 7, IL-10 levels positively correlated with IL-15
levels (Table 5). Interestingly, IL-10 levels on day 7 positively correlated with PPs on day 2.
IL-6 levels positively correlated with EGF, IL-8 and monocyte counts on day 0 (Table 5),
but not with any clinical outcomes on days 0 or 7.

Author Manuscript

MCP-1 levels positively correlated on day 0 with EGF, FGF-2, eotaxin, GM-CSF,
fractalkine, IFN-α, GRO, IL-10, IL-1RA, IL-8, MIP-1α, MIP-1β and basophil levels (Table
5). On day 7, the positive correlation between MCP-1 and EGF, FGF-2 and IL-8 persisted
but MCP-1 also positively correlated with TGF-α and VEGF levels. MCP-1 levels on day 7
also correlated with PTT levels on day 0.
On day 7, we found a negative correlation between G-CSF levels and neutrophil counts but
a positive correlation between G-CSF levels and eosinophil counts (Table 5).
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GM-CSF levels positively correlated on day 0 with several chemokines (eotaxin, GRO,
IL-8, MCP-1), cytokines (IFN-α, IL-1RA and IL-10) and growth factors (EGF, FGF-2) in
the GC group (Table 5). Similar to G-CSF, on day 7 GM-SCF levels inversely correlated
with neutrophil counts but positively correlated with eosinophil counts. None of the clinical
parameters of interest correlated with GM-CSF levels on days 0 or 7.
3. Cytokines, cell counts, CRP levels and coagulation parameters as predictors for clinical
outcomes
Based on the alterations in 5 clinical outcomes identified in our previous study[22], (P/F
ratio on day 8, plateau pressures (PP) on day 2, PCO2 levels on day 2, racemic epinephrine
requirement following extubation, and O2 requirement at PICU discharge), we set these
clinical outcomes as dependent variables and used pairwise correlations from Tables 4 and 5
as predictors for these outcomes (Tables 6A–C).
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In the placebo group, FGF levels on day 0 were negative predictors whereas IL-7 levels
were positive predictors for improved P/F ratios on day 8 (Table 6A). In the GC group,
WBC and neutrophil counts on day 0 positively predicted improved P/F ratios on day 8,
whereas fractalkine levels and lymphocyte counts on day 7 were negative predictors.
No variables from day 0 were predictive of plateau pressures in either the placebo or the GC
group (Table 6A). On day 7, IL-10 levels and lymphocyte counts were positive predictors
for plateau pressures in the placebo group, whereas IL-12(p70) levels were a negative
predictor.

Author Manuscript

Neither cytokines, nor cell counts, coagulation parameters, nor CRP levels were predictive
of PaCO2 levels on day 2 in the placebo or GC group (Table 6A).
In the placebo group, MCP-1 levels on day 0 and IFN-γ levels on day 7 were positive
predictors for racemic epinephrine requirement as were lymphocyte counts on both days 0
and 7 (Table 6B).
In the placebo group, several cytokines (IL-10, IL-1RA, IL-6, MCP-1, MIP-1β) and
lymphocyte counts from day 0 were positive predictors for supplemental O2 requirement at
ICU discharge, whereas Flt-3L and IL-17α levels were negative predictors (Table 6B). On
day 7, eotaxin, Flt-3L and IL-15 levels were positive predictors of O2 requirement at ICU
discharge, whereas IL-10 levels were a negative predictor. In the GC group, no variables
were predictive of O2 requirement at ICU discharge on day 0, but PTT levels were a
negative predictor on day 7.
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Table 6C demonstrates the r, adjusted r2 and p-ANOVA values for the described alterations
in clinical parameters and the different groups and study days.

DISCUSSION
Based on our recent pilot trial describing the effects of low-dose glucocorticoid (GC)
therapy in early pediatric ARDS[22], we identified 5 clinical parameters of interest, namely
P/F ratio on day 8, plateau pressures (PP) on day 2, PCO2 levels on day 2, racemic

Cytokine. Author manuscript; available in PMC 2017 January 01.

Schwingshackl et al.

Page 9

Author Manuscript

epinephrine requirement following extubation, and O2 requirement at PICU discharge. We
now designed this study to analyze inflammatory mediators, WBC and differential cell
counts, CRP levels and coagulation factors between placebo- and GC-treated children on
study days 0 and 7, and to determine if these parameters could explain the alterations in 5
clinical outcomes reported in our previous study[22]. Despite following all patients for up to
28 days, the number of samples collected past day 7 was too small for statistical analysis.
However, since in adults with ARDS the benefits of GC treatment occurred as far out as 32
days[25], future trials should determine the progression or resolution of inflammatory
processes past the first week of treatment.
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The pathophysiology of ARDS is not limited to the lung but is associated with a systemic
inflammatory response that provides a rationale for systemic GC therapy[26]. Interestingly,
non-resolving ARDS has been linked to GC resistance[27], while prolonged low-dose GC
therapy downregulated systemic inflammation[26]. Of note, all our measurements were
performed in plasma and not BAL samples, since BAL is not routinely performed in
pediatric ARDS patients and often has no diagnostic or therapeutic value. In addition, due to
the heterogeneous pattern of lung disease in ARDS, the technical difficulty of performing
BAL in small children and the high dilution factor of BAL fluid in a small pediatric lung,
this procedure is not standard practice in acutely ill children with ARDS.
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The only baseline difference in cytokine levels between the two groups was a higher IL-15
level in the placebo group (Table 1A and Figure 1A). IL-15 orchestrates T-cell responses
during viral infections[28] and promotes T cell differentiation[29]. Interestingly, in our
previous study[22], pneumonia and bronchiolitis were the two most common etiologies for
ARDS in both study groups. Although IL-15 establishes homeostasis of NK and CD8+ T
cells, emerging literature also links IL-15 to anti-viral T-cell responses in acute infections. In
fact, IL-15 KO mice showed lower mortality following influenza infection despite no
changes in viral loads[30] and the combination of IL-15 with hydrocortisone was a
particularly powerful activator of NK cells[31]. In our study, lymphocyte counts were
similar at baseline and at day 7, whereas total WBC and platelet counts were elevated on day
7 in the GC group (Table 3 and Figure 1C). Systemic GC treatment may plausibly cause
increased bone marrow release of WBCs, decreased vascular emargination and decreased
lung infiltration[32]. To evaluate this hypothesis, plasma, interstitial and BAL cell counts
would need to be collected simultaneously, which may be very challenging in small
children. Of note, in adults, methylprednisolone reduced BAL neutrophilia and albumin
levels[33]. Our Pearson’s correlations revealed an inverse relationship between IL-15 and
monocytes on day 0, whereas IL-15 positively correlated with MIP-1β on day 7 (Table 4).
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Furthermore, IL-15 levels positively correlated with racemic epinephrine use after
extubation and supplemental O2 at ICU discharge (Table 4), two parameters of interest
identified in our previous study[22]. It is possible that although total lymphocyte counts
were unchanged, more lymphocytes were activated by the elevated IL-15 levels in the
placebo group, resulting in increased O2 and racemic epinephrine requirements. This
hypothesis may be supported by the fact that IL-1α and IFN-γ, other T-cell cytokines, also
showed a positive correlation with O2 at ICU discharge and racemic epinephrine
requirements in the placebo group (Table 4). The multiple regression model (Tables 6A–C)
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revealed that in the placebo group on day 7, IL-15 levels positively correlated with O2
requirement at ICU discharge, but not with other clinical parameters of disease severity.
The increased IL-17α levels in the GC group on day 7 also merit further discussion (Table 3
and Figure 1C). IL-17α is closely linked to IL-22 as both cytokines coordinate aspects of
innate lung immunity[34]. A major source for these cytokines during acute infections are γδT cells and NK cells, whereas CD4+ T helper (Th17) cells contribute more to vaccineinduced immunity[34]. With the discovery of Th17 cells, a role for IL-17α in ARDS was
proposed[35]. In the lung epithelium, the primary target for IL-17α, this cytokine stimulates
the production of antimicrobial proteins, neutrophil chemoattractants and macrophage
differentiation, ultimately promoting pulmonary fibrosis[36].
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Some investigators found that early activation of the IL-1β/IL-17α axis resulted in a
proinflammatory effect and increased pulmonary fibrosis [37], whereas others showed that a
lack of γδT cell-derived IL-17α actually increased lung fibrosis[38]. In a rodent sepsis
model, IL-17α neutralization improved survival by decreasing neutrophil infiltration, IL-6
and TNF-α levels[36]. Therefore, with our current knowledge a final pro- or antiinflammatory role cannot yet be assigned to IL-17α and the timing of IL-17α peaks may
determine its function in a particular environment. Interestingly, IL-15, the only cytokine
difference between the study groups, can decrease IL-17α levels and IL-17α-mediated lung
injury[39].
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In a rodent model of LPS-induced ARDS, methylprednisolone reduced IL-17α levels and
ameliorated lung injury[40]. Although IL-17α was unchanged between the study groups, its
levels were increased in the GC group on day 7 (Table 3 and Figure 1C). We speculate that
an increase in IL-17α in the GC group could be related to the clinical improvements
reported in our previous study[22]. Interestingly, total WBC but not WBC differential
counts were elevated on day 7 in the GC group (Table 3 and Figure 1C). It is conceivable
that the increased IL-17α levels were caused by increased activation of lymphocytes without
changes in differential lymphocyte counts. Although we attempted to rescue lymphocytes
from frozen buffy coat samples to study the Th17 population, we were unable to obtain
adequate cell numbers. However, fresh lymphocytes for Th17 subtyping should be collected
in future studies.
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We also found a positive correlation of IL-17α with IL-2 levels in the GC group on day 0
(Table 5). IL-2, another T-cell cytokine, regulates T-cell proliferation, including Tregs,
which in turn regulate Th17 cells[41]. In our multiple regression model (Table 6), IL-17α
was a positive predictor for an increased O2 requirement at ICU discharge in the placebo
group, potentially indicating a proinflammatory role for IL-17α.
The alterations in IL-10 levels also appeared intriguing. IL-10 is generally considered an
anti-inflammatory cytokine and its role in ARDS is well recognized. We found no
differences in IL-10 levels between the study groups despite some improvements in clinical
disease parameters (P/F ratio, PPs, racemic epinephrine requirement, O2 requirement at ICU
discharge) as shown in our previous study[22]. Nevertheless, we found a decrease in IL-10
levels within both groups on day 7 (Tables 2 and 3, Fig 1B), potentially coupled with a
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simultaneous downregulation of several proinflammatory cytokines, such as IL-1α and IFNγ in the placebo group, and IL-6 and neutrophil chemoattractants (MCP-1, G-CSF and GMCSF) in the GC group. Despite lower neutrophil chemoattractant levels in the GC group,
differential neutrophil counts were unchanged on day 7. Elevated total WBC and platelet
counts may again be more related to a GC-induced release of hematopoietic cells and
decreased tissue emargination than chemotaxis. Nevertheless, a potential relationship
between neutrophils and IL-10 is possible, since in the placebo group several
chemoattractants, including eotaxin, GM-CSF and MCP-1 on day 0, and IL-8 and MCP-1 on
day 7 positively correlated with IL-10 levels (Table 4). In the GC group, IL-10 levels
positively correlated with neutrophil chemoattractants (GM-CSF, GRO, IL-8 and MCP-1)
before (day 0) but not after GC therapy (day 7).
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Interestingly, a positive correlation between IL-10 levels and O2 requirement at ICU
discharge, one of the clinical parameters of interest identified in our previous study[22],
occurred in the placebo group on both days 0 and 7 (Table 4) and our multiple regression
model identified IL-10 as a positive predictor for O2 requirement at ICU discharge on both
days 0 and 7 (Table 6), supporting a beneficial role of IL-10 in the resolution of ARDS.
While IL-10 levels positively correlated with plateau pressures in the GC group on day 7
(Table 5), in our multiple regression model (Table 6), IL-10 levels on day 7 predicted
improved plateau pressures in the placebo but not the GC group. Thus, it remains unclear
how IL-10 relates to the GC-mediated improvement in plateau pressures observed in our
previous study[22].
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Clear limitations of this pilot study consist in its small sample size and the lack of functional
assays uncovering the mechanistic and functional consequences of the mediators measured.
While our original study[22] was designed to show feasibility of patient recruitment,
randomization and sample collection, in this follow-up study our main goal consisted in
identifying potential ARDS biomarkers such as cytokines, cell counts, CRP levels and
coagulation parameters. Due to these limitations, we caution the reader to not draw any
major conclusions on the effects of GC therapy on clinical outcomes in pediatric ARDS
patients while the specific molecular mechanisms underlying potential GC effects in
pediatric ARDS remain to be unraveled. Nevertheless, this study unveiled that inflammatory
mediators can be successfully measured in pediatric patients with commercially available
techniques. Our correlation and regression models can aid future studies to focus on a more
concise number of molecular targets and encourage the critical mind to speculate on new
potential targets for ARDS therapies.
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GC

glucocorticoid

EGF

epidermal growth factor

FGF-2

fibroblast growth factor-2

Flt3L

fms-like tyrosine kinase 3 ligand

G-CSF

granulocyte-colony stimulating factor

GM-CSF

granulocyte monocyte-colony stimulating factor

GRO

growth related cytokine

INF-α2

interferon-α2

IFN-γ

interferon-γ

IL-1α

interleukin1α

IL-1β

interleukin-1β

IL-1ra

interleukin-1 receptor antagonist

IL-2

interleukin-2

IL-3

interleukin-3

IL-4

interleukin-4

IL-5

interleukin-5

IL-6

interleukin-6

IL-7

interleukin-7

IL-8

interleukin-8

IL-9

interleukin-9

IL-10

interleukin-10

IL-12(p40)

interleukin-12(p40)

IL-12(p70)

interleukin-12(p70)

IL-13

interleukin-13

IL-15

interleukin-15

IL-17α

interleukin-17α

IP-10

interferon-inducible protein-10

MCP-1

monocyte chemotactic protein-1

MCP-3

monocyte chemotactic protein-3

MDC

macrophage-derived chemokine

MIP-1α

macrophage inhibitory protein-1α

MIP-1β

macrophage inhibitory protein-1β
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sCD40L

soluble CD40 ligand

TGF-α

transforming growth factor-α

TNF-α

tumor necrosis factor-α

TNF-β

tumor necrosis factor-β

VEGF

vascular endothelial growth factor

WBC

white blood cells

PT

prothrombin time

PTT

partial thromboplastin time

CRP

C-reactive protein

ICU

intensive care unit
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1.

A recent RCT in pediatric ARDS patients showed that low-dose glucocorticoid
therapy in pediatric ARDS patients is feasible and may improve both ventilation
and oxygenation indices.

2.

The molecular mechanisms underlying potential changes in these outcomes
remained unclear.

3.

This study was designed to examine the effects of intravenous
methylprednisolone on circulating inflammatory biomarkers in pediatric ARDS
patients.

4.

We show the feasibility of simultaneously measuring multiple inflammatory
cytokines, cell counts and coagulation parameters in pediatric ARDS patients.

5.

We report statistical models that may be useful for future, larger trials to predict
ARDS severity and outcomes.
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Figure 1. Comparisons of inflammatory meditators
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Figure 1A shows comparisons of cytokine levels and cell counts between the placebo and
the glucocorticoid (GC) groups on days 0 and 7. Using an unpaired 2-tailed t-test with a pvalue of <0.05 as our level of significance (*), the only alteration in cytokine levels was an
elevated IL-15 concentration [pg/mL] in the placebo group on day 0 and a higher basophil
count in the placebo group on day 7; (mean±SEM).
Figure 1B shows decreased IL-1α, IFN-γ and IL-10 levels in the placebo group on day 7
(D7), and decreased IL-10 levels in the GC group on day 7. Cytokine concentrations are
depicted in pg/mL (mean±SEM). A p-value of <0.05 was considered significant (#).
Figure 1C shows elevated IL-17α levels and decreased IFN-α, IL-6, MCP-1, G-CSF and
GM-CSF levels on day 7 (D7) in the glucocorticoid (GC) group. Cytokine concentrations
are depicted in pg/mL (mean±SEM). IL-17α levels were analyzed using an unpaired t-test
(indicated by ^). The rest of the cytokine levels were analyzed using a 2-tailed MannWhitney test based on a Fisher test and data are depicted as median±SE. A p-value of <0.05
was considered significant (#).
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Comparison of cytokine levels and cell counts between placebo and the glucocorticoid
(GC) groups on days 0 and 7
Table 1A shows an increased IL-15 concentration on day 0 and Table 1B an increased basophil count on day 7
in the placebo group; n=number of subjects. A p-value <0.05 was considered significant.
A
Placebo
n=8

GC
n=11

P

-

0.012

Day 0
IL - 15↑
B
Placebo
n=5

Author Manuscript

GC
n=6

P

-

0.008

Day 7
basophils ↑
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Comparison of cytokine levels within the placebo group between days 0 (D0) and 7 (D7): ↓ arrows indicate a
decrease in cytokine levels. (*) indicate data analyzed using an unpaired 2-tailed t-test, whereas IL-10 levels
were analyzed using a 2-tailed Mann-Whitney test based on a Fisher test. A p-value of <0.05 was considered
significant (#). n=number of subjects.
Placebo Days 0 vs 7
Cytokines:

p

n: day 0, day 7

IL–1a* ↓

0.036

6,6

INF–y*↓

0.037

6,6

IL–10 ↓

0.002

7,6
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Comparison of cytokine levels within the glucocorticoid (GC) group between days 0 (D0) and 7 (D7): ↑ and ↓
arrows indicate an increase or decrease in cytokine levels, respectively. IL-17α levels were analyzed using an
unpaired t-test (indicated by ^) and are depicted as mean±SEM. The rest of the cytokine levels were analyzed
using a 2-tailed Mann-Whitney test based on a Fisher test. A p-value of <0.05 was considered significant (#).
n=number of subjects.
GC Days 0 vs 7
Cytokines:
IL-17a^

p

n: day 0, day 7

Author Manuscript

0.045

5,2

INF-α ↓

0.026

6,6

IL-6 ↓

0.003

7,6

IL-10 ↓

0.035

7,6

MCP-1 ↓

0.004

7,8

G-CSF ↓

0.004

4,8

GM-CSF ↓

0.026

7,7

WBCs ↑

0.041

8,7

platelets ↑

0.034

8,7

↑
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Placebo group Pearson’s correlation table showing pairwise comparisons of cytokine levels, cell counts and
clinical parameters of disease severity: r is the Pearson’s correlation coefficient. A p-value of <0.01 was
considered significant and was derived from a paired, 2-tailed t-test. n=number of subjects (Day 0: cytokines
n=8–18, cell counts n=18, clinical parameters of disease severity n=17. Day 7: cytokines n=3–7, cell counts
n=7, clinical parameters of disease severity n=7).
IL-15
Placebo Day 0

r

p

Author Manuscript

monocytes

−1.0

0.001

Placebo Day 7

r

p

MIP-1β

1.0

0.007

O2 at discharge

1.0

0.001

Racemic epi

1.0

0.001

IL-1α
Placebo Day 0

r

p

Author Manuscript

eotaxin

0.9

0.001

GM-CSF

1.0

≤0.000

IL-10

1.0

≤0.000

IL-7

1.0

0.002

MIP-1α

0.8

0.005

MIP-1β

0.9

0.001

TNF-α

0.9

≤0.000

lymphocytes

0.8

0.008

O2 at discharge

0.8

0.008

IFN-y
Placebo Day 0

r

p

Flt-3L

1.0

0.002

fractalkine

0.7

0.002

IL-17α

0.9

0.002

IL-1RA

0.7

0.007

IP-10

0.9

≤0.000

Placebo Day 7

r

p

racemic epi

0.9

0.006

Author Manuscript

IL-10
Placebo Day 0

r

p

eotaxin

0.9

≤0.000

Flt-3L

1.0

0.003

GM-CSF

0.9

≤0.000
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IL-10
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Placebo Day 0

r

p

IL-1RA

0.7

≤0.000

IL-1α

1.0

≤0.000

IL-6

0.8

≤0.000

IL-7

1.0

≤0.000

IP-10

0.8

≤0.000

MCP-1

0.7

0.001

MIP-1β

0.9

≤0.000

TNF-α

0.9

≤0.000

PT

1.0

0.001

PTT

1.0

≤0.000

O2 at transfer

0.8

≤0.000
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Placebo Day 7

r

p

FLt-3L

1.0

0.008

IL-6

1.0

0.003

IL-8

1.0

≤0.000

MCP-1

1.0

0.001

MIP-1α

1.0

0.007

O2 at discharge

1.0

≤0.000
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Glucocorticoid (GC) group Pearson’s correlation table showing pairwise comparisons of cytokine levels, cell
counts and clinical parameters of disease severity: r is the Pearson’s correlation coefficient. A p-value of <0.01
was considered significant and was derived from a paired, 2-tailed t-test. n=number of subjects (Day 0:
cytokines n=8–16, cell counts n=16, clinical parameters of disease severity n=16. Day 7: cytokines n=6–8, cell
counts n=8, clinical parameters of disease severity n=8).
IL-17α
GC Day 0

r

p

IL-2

1.0

0.008

IFN-α

Author Manuscript

GC Day 0

r

p

IL-1RA

0.8

0.002

IL-7

0.8

0.008

IL-8

0.9

≤0.000

MCP-1

0.8

0.001

monocytes

0.7

0.007

GC Day 7

r

p

monocytes

0.9

0.008

IL-10
Steroid Day 0

r

p

Author Manuscript

EGF

0.7

0.007

fractalkine

0.8

0.002

INF-α

0.7

0.006

GRO

0.7

0.003

IL-1RA

0.7

0.004

IL-8

0.7

0.008

MCP-1

0.7

0.003

MIP-1α

0.7

0.006

GC Day 7

r

p

IL-15

1.0

0.009

PP Day 2

0.9

0.004

MCP-1

Author Manuscript

GC Day 0

R

p

EGF

0.8

0.002

FGF-2

0.8

0.001

eotaxin

0.9

≤0.000

GM-CSF

0.9

≤0.000

fractalkine

0.8

≤0.000
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MCP-1
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GC Day 0

R

p

IFN-α

0.8

0.001

GRO

0.9

≤0.000

IL-10

0.7

0.003

IL-1RA

1.0

≤0.000

IL-8

0.7

0.001

MIP-1α

0.8

0.008

MIP-1β

0.7

0.006

basophils

0.9

≤0.000

GC Day 7

r

p

EGF

1.0

0.002

Author Manuscript

FGF-2

1.0

0.002

TGF-α

1.0

0.008

IL-8

1.0

≤0.000

VEGF

0.9

0.003

PTT-Day 0

0.9

0.005

G-CSF
GC Day 7

r

p

neutrophils

−0.9

0.008

eosinophils

0.9

0.005

GM-CSF

Author Manuscript

GC Day 0

r

p

eotaxin

0.7

0.007

GRO

0.8

≤0.000

IL-8

0.8

≤0.000

MCP-1

0.9

≤0.000

EGF

0.9

0.001

FGF-2

0.8

≤0.000

IFN-α

0.9

≤0.000

IL-1RA

0.9

≤0.000

IL-10

0.7

0.0074

GC Day 7

r

p

neutrophils

−0.9

0.008

eosinophils

0.9

0.006

Author Manuscript

IL-6
GC Day 0

r

p

EGF

0.9

0.002

IL-8

0.8

0.002
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IL-6

Author Manuscript

GC Day 0

r

p

monocytes

0.7

0.004

Author Manuscript
Author Manuscript
Author Manuscript
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Table 6

Author Manuscript

Tables 6A and B. Multiple regression models based on clinical parameters of disease severity identified in our
previous study[22] using the least squared method.
Table 6C reports the Pearson’s r, adjusted r2 and p-ANOVA values for the data in Tables 6A and B.
Tables 6A
P/F ratio day 8
vs placebo D0, n=7

Coefficients

SE

p

Intercept

227

14.7

≤0.000

FGF-2

−2.480

0.266

0.001

IL-7

11.4

1.910

0.004

vs placebo D7, n=5

Coefficients

SE

P

none

Author Manuscript

vs GC, n=9

Coefficients

SE

p

Intercept

119.044

41.933

0.025

WBC

5.386

5.956

0.396

Neutrophils

1.855

1.283

0.192

vs GC D7, n=7

Coefficients

SE

p

Intercept

456.169

23.987

≤0.000

fractalkine

−1.256

0.360

0.025

lymphocytes

−2.419

0.646

0.020

PP day 2
vs placebo D0, n=18

Coefficients

SE

P

Author Manuscript

none
vs placebo D7, n=17

Coefficients

SE

P

Intercept

7.743

0.497

0.001

IL-10

0.115

0.006

≤0.000

IL-12P70

−0.005

0.001

0.002

lymphocytes

0.071

0.004

≤0.000

vs GC D0, n=15

Coefficients

SE

p

Coefficients

SE

p

none
vs GC D7, n=8
none

Author Manuscript

PaCO2 day 2
vs placebo D0, n=18

Coefficients

SE

P

Coefficients

SE

P

none
vs placebo D7, n=17
none
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Coefficients

SE

P

Coefficients

SE

P

none

Author Manuscript

vs GC D7, n=8
none
Tables 6B

Racemic epinephrine

Author Manuscript

vs placebo D0, n=17

Coefficients

SE

P

Intercept

0.755

0.216

0.004

MCP-1

≤0.000

≤0.000

0.016

lymphocytes

0.015

0.005

0.012

vs placebo D7, n=7

Coefficients

SE

P

Intercept

0.175

0.154

0.318

IFN-y

0.083

0.021

0.017

lymphocytes

0.017

0.006

0.039

vs GC D0, n=16

Coefficients

SE

p

none
vs GC D7, n=8

Coefficients

SE

p

none
O2 at discharge

Author Manuscript

vs placebo D0, n=17

Coefficients

SE

P

Intercept

2.017

0.008

≤0.000

Flt-3L

−0.002

≤0.000

0.001

IL-10

≤0.000

≤0.000

0.001

IL-1RA

≤0.000

≤0.000

≤0.000

IL-6

≤0.000

≤0.000

0.004

MCP-1

≤0.000

≤0.000

0.013

MIP-1β

0.001

≤0.000

≤0.000

lymphocytes

≤0.000

≤0.000

0.007

vs placebo D7, n=7

Coefficients

SE

P

Author Manuscript

Intercept

1.933

0.004

≤0.000

eotaxin

≤0.000

≤0.000

0.010

Fit-3L

≤0.000

≤0.000

0.003

IL-10

−0.002

≤0.000

0.008

IL-15

0.027

0.001

0.001

vs GC D0, n=16

Coefficients

SE

P

none
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Author Manuscript

vs GC D7, n=6

Coefficients

SE

P

Intercept

3.711

0.157

≤0.000

PTT

−0.009

0.005

0.168

Table 6C
P/F ratio day 8

r

Adjusted r2

p-ANOVA

vs placebo day 0

0.097

0.935

0.002

vs GC day 0

0.833

0.694

0.016

vs placebo day 7

0.978

0.932

0.002

vs GC day 7

0.978

0.932

0.002

vs placebo day 0

none

-

-

vs GC day 0

none

-

-

vs placebo day 7

1

1

≤0.000

vs GC day 7

none

-

-

vs placebo day 0

none

-

-

PP day 2

Author Manuscript

PaCO2 day 2

Author Manuscript

vs GC day 0

none

-

-

vs placebo day 7

none

-

-

vs GC day 7

none

-

-

vs placebo day 0

0.809

0.604

0.001

vs GC day 0

none

-

-

vs placebo day 7

0.978

0.936

0.002

vs GC day 7

none

-

-

vs placebo day 0

1

1

≤0.000

vs GC day 0

none

-

-

vs placebo day 7

1

1

≤0.000

vs GC day 7

0.991

0.970

0.002

Racemic epinephrine

O2 at transfer

Author Manuscript
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